A live bio-therapeutic for mastitis, containing Lactococcus lactis DPC3147 with comparable efficacy to antibiotic treatment

Show simple item record

dc.contributor.author Kitching, Michael
dc.contributor.author Mathur, Harsh
dc.contributor.author Flynn, James
dc.contributor.author Byrne, Noel
dc.contributor.author Dillon, Pat
dc.contributor.author Sayers, Riona
dc.contributor.author Rea, Mary C.
dc.contributor.author Hill, Colin
dc.contributor.author Ross, R. Paul
dc.date.accessioned 2019-10-23T03:59:28Z
dc.date.available 2019-10-23T03:59:28Z
dc.date.issued 2019-08-27
dc.identifier.citation Kitching, M., Mathur, H., Flynn, J., Byrne, N., Dillon, P., Sayers, R., Rea, M. C., Hill, C. and Ross, R. P. (2019) 'A Live Bio-Therapeutic for Mastitis, Containing Lactococcus lactis DPC3147 With Comparable Efficacy to Antibiotic Treatment', Frontiers in Microbiology, 10, 2220. (11pp.) DOI: 10.3389/fmicb.2019.02220 en
dc.identifier.volume 10 en
dc.identifier.startpage 1 en
dc.identifier.endpage 11 en
dc.identifier.uri http://hdl.handle.net/10468/8818
dc.identifier.doi 10.3389/fmicb.2019.02220 en
dc.description.abstract Bovine mastitis is an ongoing significant concern in the dairy and agricultural industry resulting in substantial losses in milk production and revenue. Among the predominant etiological agents of bovine mastitis are Staphylococcus aureus, Streptococcus uberis, Streptococcus dysgalactiae, and Escherichia coli. Currently, the treatment of choice for bovine mastitis involves the use of commercial therapeutic antibiotic formulations such as TerrexineTM, containing both kanamycin and cephalexin. Such antibiotics are regularly administered in more than one dose resulting in the withholding of milk for processing for a number of days. Here, we describe the optimization of a formulation of Lactococcus lactis DPC3147, that produces the two-component bacteriocin lacticin 3147, in a liquid paraffin-based emulsion (formulation hereafter designated ‘live bio-therapeutic’) for the first time and compare it to the commercial antibiotic formulation TerrexineTM, with a view to treating cows with clinical/sub-clinical mastitis. Critically, in a field trial described here, this ‘ready-to-use’ emulsion containing live L. lactis DPC3147 cells exhibited comparable efficacy to TerrexineTM when used to treat mastitic cows. Furthermore, we found that the L. lactis cells within this novel emulsion-based formulation remained viable for up to 5 weeks, when stored at 4, 22, or 37°C. The relative ease and cost-effective nature of producing this ‘live bio-therapeutic’ formulation, in addition to its enhanced shelf life compared to previous aqueous-based formulations, indicate that this product could be a viable alternative therapeutic option for bovine mastitis. Moreover, the single-dose administration of this ‘live bio-therapeutic’ formulation is a further advantage, as it can expedite the return of the milk to the milk pool, in comparison to some commercial antibiotics. Overall, in this field trial, we show that the live bio-therapeutic formulation displayed a 47% cure rate compared to a 50% cure rate for a commercial antibiotic control, with respect to curing cows with clinical/sub-clinical mastitis. The study suggests that a larger field trial to further demonstrate efficacy is warranted. en
dc.description.sponsorship Enterprise Ireland (Project Code CF/2015/0122A) en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher Frontiers Media en
dc.relation.uri https://www.frontiersin.org/articles/10.3389/fmicb.2019.02220/full
dc.rights ©2019 Kitching, Mathur, Flynn, Byrne, Dillon, Sayers, Rea, Hill and Ross. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. en
dc.rights.uri http://creativecommons.org/licenses/by/4.0/ en
dc.subject Mastitis en
dc.subject Emulsion en
dc.subject Lacticin 3147 en
dc.subject Somatic cell counts en
dc.subject Antibiotics en
dc.title A live bio-therapeutic for mastitis, containing Lactococcus lactis DPC3147 with comparable efficacy to antibiotic treatment en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Paul Ross, School of Microbiology, University College Cork, Cork, Ireland. +353-21-490-3000 Email:p.ross@ucc.ie en
dc.internal.availability Full text available en
dc.description.version Published Version en
dc.contributor.funder Enterprise Ireland en
dc.contributor.funder Science Foundation Ireland en
dc.description.status Peer reviewed en
dc.identifier.journaltitle Frontiers in Microbiology en
dc.internal.IRISemailaddress p.ross@ucc.ie en
dc.identifier.articleid 2220 en
dc.relation.project info:eu-repo/grantAgreement/SFI/SFI Research Centres/12/RC/2273/IE/Alimentary Pharmabiotic Centre (APC) - Interfacing Food & Medicine/ en
dc.identifier.eissn 1664-302X


Files in this item

This item appears in the following Collection(s)

Show simple item record

©2019 Kitching, Mathur, Flynn, Byrne, Dillon, Sayers, Rea, Hill and Ross. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Except where otherwise noted, this item's license is described as ©2019 Kitching, Mathur, Flynn, Byrne, Dillon, Sayers, Rea, Hill and Ross. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement